
    
      This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose
      escalation study of ION904 in up to 72 participants. Following a Screening Period of up to 28
      days, eligible healthy participants will be randomized to treatment and receive a single,
      subcutaneous (SC) dose of the assigned study drug. Participants will be followed for up to 13
      weeks after dosing.
    
  